Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome.
Circulating IgG-immune complexes (IgG-IC) play a role in the complex etiology of C-HUS. In an ongoing open clinical study protein A immunoadsorption treatment is carried out for patients who developed severe forms of the syndrome after mitomycin-C chemotherapy. So far, successful treatment of 14 out of 19 evaluable patients was possible. A protein A immunoadsorption system was used, allowing processing of large plasma volumes to eliminate IgG and IgG-IC from the patient's plasma.
Borghardt
E J
EJ
Department of Hematology/Oncology (Tumor-Center Hanover), Germany.
Kirchertz
E J
EJ
Marten
I
I
Fenchel
K
K
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced / Q000276:immunology*; D006801:Humans; D007163:Immunosorbent Techniques; D016685:Mitomycin / Q000009:adverse effects*; D013205:Staphylococcal Protein A / Q000302:isolation & purification*